ストックスクリーナーアプリを入手
12.17
7.70%
0.87
アフターアワーズ：
12.30
0.13
+1.07%
Novocure Ltd (NVCR) 最新ニュース
Is NovoCure’s (NVCR) Leadership Consolidation Clarifying Its Innovation Strategy Or Complicating Governance Signals? - simplywall.st
NovoCure Ltd (NVCR) Stock Up 5.4% and Still Undervalued -- GF Sc - GuruFocus
NVCR SEC FilingsNovocure 10-K, 10-Q, 8-K Forms - Stock Titan
Assessing NovoCure (NVCR) Valuation After Prolonged Share Price Weakness And Undervalued Narrative - simplywall.st
NovoCure Unifies Clinical And Innovation Roles As Market Discounts Persist - Sahm
NovoCure Ltd (NVCR) Stock Down 3.8% -- Now Undervalued? GF Score: 66/100 - GuruFocus
NovoCure Limited Increases Compensation for Dr. Uri Weinberg Upon Appointment as Chief Medical Officer - Minichart
Novocure increases executive compensation as Uri Weinberg takes on dual roles By Investing.com - Investing.com South Africa
Novocure increases executive compensation as Uri Weinberg takes on dual roles - Investing.com
NovoCure appoints Uri Weinberg as Chief Medical Officer alongside Chief Innovation Officer - TradingView — Track All Markets
NovoCure (NASDAQ: NVCR) boosts pay as Uri Weinberg assumes CMO duties - Stock Titan
NovoCure (BSP:N2VC34) Net Investment Income - GuruFocus
NovoCure (BSP:N2VC34) Other Assets for Insurance Companies - GuruFocus
NovoCure (BSP:N2VC34) Dividend Yield % : 0.00% (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Other Net Income (Loss) : R$0 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) 6-1 Month Momentum % : N/A% (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Cash Flow from Discontinued Operations : R$0 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) PEG Ratio : N/A (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Gross-Profit-to-Asset % : 49.36% (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Shiller PE Ratio : (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Purchase Of Investment : R$-4,539 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Operating Income : R$-851 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Minority Interest : R$0.00 Mil (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) 3-1 Month Momentum % : N/A% (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Investments And Advances : R$0 Mil (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Non Operating Income : R$0 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) 1-Year Sharpe Ratio : N/A (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Retained Earnings : R$-7,040 Mil (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Interest and Commission Paid - GuruFocus
NovoCure (BSP:N2VC34) Inventories, Other : R$-0 Mil (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Forward Dividend Yield % : 0.00% (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Graham Number : R$N/A (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) PE Ratio (TTM) : At Loss (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Cyclically Adjusted PS Ratio : (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Other Long-Term Liabilities : R$0 Mil (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Other Current Assets : R$106 Mil (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Gross Property, Plant and Equipment : R$1,180 Mil (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Total Operating Expense : R$3,550 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Purchase Of Business : R$0 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Sale Of Business : R$0 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Dividend Payout Ratio : 0.00 (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Cyclically Adjusted Price-to-FCF : (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Net Policyholder Benefits/Claims - GuruFocus
NovoCure (BSP:N2VC34) Policyholder Funds - GuruFocus
BSP:N2VC34 EBITDA: R$-581 Mil | Possible Value Trap - GuruFocus
NovoCure (BSP:N2VC34) Goodwill : R$0 Mil (As of Dec. 2025) - GuruFocus
BSP:N2VC34 OCF Yield %: -3.95 | Possible Value Trap - GuruFocus
NovoCure (BSP:N2VC34) Other Operating Expense : R$-0 Mil (TTM As of Dec. 2025) - GuruFocus
BSP:N2VC34 EV-to-EBITDA: 0.72 | Possible Value Trap - GuruFocus
BSP:N2VC34 Accounts Payable: R$667 Mil | Possible Value Trap - GuruFocus
BSP:N2VC34 FCF Margin %: -13.13% | Possible Value Trap - GuruFocus
NovoCure Ltd (BSP:N2VC34) DCF Valuation - GuruFocus
NovoCure Ltd (BSP:N2VC34) Dividend - GuruFocus
NovoCure (BSP:N2VC34) Net Issuance of Preferred Stock : R$0 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Fees and Other Income - GuruFocus
BSP:N2VC34 Total Payout Ratio: 0.02 | Possible Value Trap - GuruFocus
NovoCure (BSP:N2VC34) Net Loan - GuruFocus
NovoCure (BSP:N2VC34) Cash from Discontinued Operating Acti - GuruFocus
NovoCure (BSP:N2VC34) Sale Of Property, Plant, Equipment : R$0 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Total Tax Payable : R$0 Mil (As of Dec. 2025) - GuruFocus
BSP:N2VC34 Tax Provision: R$-1 Mil | Possible Value Trap - GuruFocus
NovoCure (BSP:N2VC34) Gross Loan - GuruFocus
NovoCure (BSP:N2VC34) Payments to Suppliers for Goods and S - GuruFocus
NovoCure (BSP:N2VC34) Marketable Securities : R$1,932 Mil (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Cash Flow for Dividends : R$0 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Margin of Safety % (DCF Earnings Based) : N/A (As of Apr. 09, 2026) - GuruFocus
BSP:N2VC34 EBITDA per Share: R$-5.22 | Possible Value Trap - GuruFocus
NovoCure (BSP:N2VC34) Price-to-Owner-Earnings : (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Other Stockholders Equity : R$0 Mil (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Change In Prepaid Assets : R$0 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Degree of Operating Leverage : -0.16 (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Earnings Yield % : N/A% (As of Apr. 09, 2026) - GuruFocus
2.40%
0.00%
大文字化:
|
ボリューム (24 時間):